Development

Affinicon has identified its first medical indication within
inflammation and produced the first humanized antibody
conjugate drug for anti-inflammatory therapy.

Affinicon has obtained proof of concept in animal models for the
unique combination of high efficacy/low side-effects
characterising the Affinicon platform by testing its lead drug
candicte Cymac-001 in rats and pigs. Macrophage targeting is
enabling a substantial dose reduction (factor 50) of dexamethasone
to achieve anti-inflammatory efficacy comparable to free
dexamethasone.